Clinical Trial

Comparison of Response Between Combination of Transarterial Chemoembolization and Lenvatinib Therapy Versus Lenvatinib Monotherapy in Patients With Unresectable Hepatocellular Carcinoma

Recruiting
View on ClinicalTrials.gov →
Summary
The goal of this interventional study is to compare treatment response between transarterial chemoembolization (TACE) combined with lenvatinib and lenvatinib monotherapy in patients with unresectable hepatocellular carcinoma. The study aims to determine whether the addition of TACE to lenvatinib results in improved tumor response compared with lenvatinib alone in a real-world clinical setting.
Trial Details
NCT Number NCT07408804
Lead Sponsor Bangladesh Medical University
Conditions Unresectable Hepatocellular Carcinoma (HCC)
Enrollment 40 participants
Start Date 2025-04-08
Primary Completion 2026-09-30 (estimated)
Study Completion 2026-09-30 (estimated)
Updated on ClinicalTrials.gov 2026-02-13